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A recent genome-wide association study (GWAS) reported evidence for association between
rs1344706 within ZNF804A (encoding zinc-finger protein 804A) and schizophrenia
(P=1.61 107), and stronger evidence when the phenotype was broadened to include bipolar
disorder (P=9.96 109). In this study we provide additional evidence for association through
meta-analysis of a larger data set (schizophrenia/schizoaffective disorder N=18 945, schizo-
phrenia plus bipolar disorder N=21 274 and controls N=38 675). We also sought to better
localize the association signal using a combination of de novo polymorphism discovery in
exons, pooled de novo polymorphism discovery spanning the genomic sequence of the locus
and high-density linkage disequilibrium (LD) mapping. The meta-analysis provided evidence
for association between rs1344706 that surpasses widely accepted benchmarks of signifi-
cance by several orders of magnitude for both schizophrenia (P=2.5 1011, odds ratio (OR)
1.10, 95% confidence interval 1.07–1.14) and schizophrenia and bipolar disorder combined
(P=4.1 1013, OR 1.11, 95% confidence interval 1.07–1.14). After de novo polymorphism
discovery and detailed association analysis, rs1344706 remained the most strongly associated
marker in the gene. The allelic association at the ZNF804A locus is now one of the most
compelling in schizophrenia to date, and supports the accumulating data suggesting
overlapping genetic risk between schizophrenia and bipolar disorder.
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Introduction
Genetic epidemiology reveals that genes account for
> 80% of the population variance in risk1,2 of schizo-
phrenia. Numerous genetic associations to schizo-
phrenia have been reported, but which of these, if
any, are true associations remains widely disputed.3
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The advent of genome-wide association study
(GWAS) technology has recently proven to be suc-
cessful in allowing the identification of strongly
supported genetic associations for many other com-
mon phenotypes, and this is now true for schizo-
phrenia.4–7
Recently, we undertook a GWAS of 479 UK
schizophrenia cases and 2937 controls,4 with follow-
up of the strongest findings in approximately 17000
subjects. In the combined data set of approximately
20 000 subjects, the single-nucleotide polymorphism
(SNP) with the strongest evidence for association
(P=1.61 107) to schizophrenia was rs1344706
within ZNF804A (encoding zinc-finger protein
804A). Although this falls short of a widely accepted
threshold for genome-wide significant association of
P<7.2108,8 we did obtain evidence that surpasses
this (P=9.96109), when the phenotype was broa-
dened to include patients with bipolar disorder, a
phenotype for which there is considerable overlap in
clinical features and increasing epidemiological and
molecular genetic evidence for shared genetic risk
with schizophrenia.9 Subsequently, independent as-
sociations between schizophrenia and the same allele
of rs1344706 have been reported by the International
Schizophrenia Consortium,5 The Irish Case/Control
Study of Schizophrenia10 and the SGENE-plus con-
sortium.11 In a total of over 5000 patients with
psychiatric disorders, the latter11 also reported three
copy number variants (CNVs) at the ZNF804A locus, a
deletion in an individual with schizophrenia, a
duplication in an individual with bipolar disorder
and a deletion in an individual with anxiety disorder.
This contrasted with no CNVs at the locus in almost
40 000 controls (P=0.0016). From additional reported
data sets, they also noted duplication CNVs in three
people with autism, and an additional three CNVs out
of a total of approximately 12 000 controls, two of
whom were < 18 years and were therefore not past the
characteristic age at onset for schizophrenia. Overall,
the CNV data suggest that rare structural variants at
the ZNF804A locus may also be involved in the risk of
a range of psychiatric disorders, although support for
this is not unequivocal.
As our GWAS4 was based upon fewer than 1/20th of
all common SNPs in the genome, it seemed unlikely
that the best associated SNP in our study was the true
functional variant. In the present study, we tried to
localize the association signal using a combination of
de novo polymorphism discovery targeted at exons,
pooled de novo polymorphism discovery spanning
the genomic sequence of the locus and high-density
linkage disequilibrium (LD) mapping. rs1344706, the
SNP originally highlighted by the original GWAS
study, remained the most strongly associated SNP at
the locus. The evidence for association for rs1344706
was further tested by a meta-analysis of approxi-
mately 60 000 subjects (schizophrenia/schizoaffective
disorder N=18 945, schizophrenia plus bipolar dis-
order N=21274 and controls N=38675) derived from
the original publication and additional data sets. The
overall statistical support in schizophrenia surpassed
genome-wide significance (P=2.51011) by more
than three orders of magnitude, as did the support in
schizophrenia and bipolar disorder combined
(P=4.11013). Moreover, the evidence for associa-
tion in replication samples (that is, after exclusion of
the discovery GWAS) was also genome-wide signifi-
cant, making rs1344706 in ZNF804A the most
robustly supported common allele for schizophrenia
reported to date. The strength of the findings also
strongly support accumulating data that genetic risk
for schizophrenia and bipolar disorder12 overlap.
Materials and methods
Targeted de novo polymorphism discovery in exons
Coding sequences were screened for polymorphisms
in 163 UK individuals with schizophrenia and 135
UK blood donor controls. Genomic sequences corre-
sponding to all exons were extracted from the UCSC
Genome Browser (March 2006), based upon Refseq
transcript NM_194250. Amplicons with a maximum
length of 500 bp (n=13) were designed to span coding
exons plus a minimum of 72 bases of flanking
sequence. Where multiple amplicons were required
to cover an exon, these overlapped by a minimum of
81 bp. High-resolution melting analysis was per-
formed for 11 amplicons using a LightScanner (Idaho
Technologies, Salt Lake City, Utah, USA) according to
the manufacturer’s instructions. Potential DNA var-
iants identified by this approach were characterized
by sequencing the relevant PCR product using BigDye
chemistry on a 3100 capillary sequencer (Applied
Biosystems, Foster City, CA, USA). Two amplicons
failed to optimize in the presence of the high-
resolution melting analysis detection reagent and
were screened for variants by sequencing. Identified
SNPs were genotyped in the CEU HapMap trios to
assess their LD relationships and to detect Mendelian
inconsistencies (of which there were none).
Identification of SNPs associated with ZNF804A
expression (eQTLs)
To identify SNPs that might be expression quantita-
tive trait loci (eQTLs), we extracted genotype and
ZNF804A lymphoblastoid expression data from the
CEU HapMap samples deposited in GeneVar (http://
www.sanger.ac.uk/humgen/genevar/). To analyse these
data, we used the method described by the group that
developed the database.13
Association studies
Functional and tagSNP (fatSNP) study. A two-stage
fatSNP study was designed to extract a high
proportion of the known genetic variation spanning
ZNF804A (chr2:184958600–185722680, National
Center for Biotechnology Information (NCBI) b36),
with putative functional variants given particular
priority. Details of all samples used in these two
stages of the study are given in our previous
manuscript.4
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fatSNP stage 1. SNPs: We aimed to tag at r2 = 1 all
SNPs with minor allele frequency (MAF) of X0.01 in
the HapMap CEU samples plus SNPs identified by de
novo polymorphism discovery of exons. This panel of
SNPs was derived using Tagger (Haploview, version
4.114) with forced inclusion of all synonymous and
non-synonymous variants identified by de novo
discovery and from public databases, and all SNPs
associated with expression of ZNF804A mRNA in the
GeneVar database. We also force included SNPs
previously genotyped in the previous GWAS.4
Samples: In fatSNP stage 1 (fatSNP1), the resultant
set of SNPs (excluding those for which data were
already available from the GWAS study) were
genotyped in a subset of the GWAS samples from
the earlier study.4 This fatSNP1 sample comprised
479 UK cases with schizophrenia and the 1958 birth
cohort control sample (N=1445) used by the Well-
come Trust Case/Control Consortium (WTCCC)15 that
we had also used in our GWAS study. The results of
fatSNP1 were used to select SNPs for follow-up in
additional samples using criteria detailed below.
fatSNP stage 2. SNPs: For follow-up in fatSNP stage 2
(fatSNP2), we identified all markers that were
associated with Pp1 104 in fatSNP1, or that had
surpassed that threshold in the GWAS study. We
additionally followed up non-synonymous SNPs that
were associated with Pp0.10 in those analyses. To
prune the marker set, we applied a highly conservative
definition of non-redundancy, removing one of any pair
of markers that were highly correlated (r2X0.97) in the
fatSNP1 sample.
Samples: For fatSNP phase 2, we genotyped the UK
National Blood Service controls (N=1428) used by
the WTCCC,15 which we had also used in our GWAS
study, and additional UK schizophrenia samples
(N=163) for whom GWAS array data were not
available, which we had used as part of the follow-
up sample in the previous publication.4 The com-
bined set of UK cases (N=642) and blood donor/1958
birth cohort controls (N= 2873 available for in-house
genotyping, N= 2937 with Affymetrix, Santa Clara,
CA, USA; 500K data) are subsequently referred to for
brevity as the Cardiff Full sample. fatSNP2 also
included three additional case–control series from
Bulgaria, Ireland (referred to as the Dublin sample)
and Germany (referred to as the Munich sample), the
combination of which is referred to, for brevity (and
consistency with the previous paper), as REP1 and
comprises an additional 1664 cases and 3541 controls.
All cases met DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders-fourth edition) criteria for
schizophrenia; full details of these samples are given in
our previous study.4 The results of the REP1 sample
were combined with those of the Cardiff Full sample to
derive an overall fatSNP2 P-value as described below.
fatSNP genotyping and analysis
Most SNP assays for the fatSNP studies were genotyped
in the Cardiff laboratory using the Sequenom iPlexGold
system (San Diego, CA, USA). Additional SNPs were
genotyped in Cardiff using TaqMan (on demand)
probes (Applied Biosystems; rs17584522) or Ampli-
fluor AssayArchitect (Millipore, Billerica, MA, USA;
rs12476147) using an Analyst AD fluorometer (Mole-
cular Devices, Silicon Valley, CA, USA). In addition,
rs17584522 was genotyped by the Dublin group with
TaqMan (on demand) probes using a 7900HT Sequence
Detection System (Applied Biosystems). For SNPs for
which we could not design a reliable assay using either
method, we genotyped the HapMap CEU sample using
SNaPshot chemistry (Applied Biosystems) and a 3100
capillary sequencer (Applied Biosystems). For
rs5836928, a 3bp insertion deletion, we genotyped
the HapMap CEU sample using fluorescently tagged
primers with genotypes discriminated by size using a
3100 capillary sequencer (Applied Biosystems).
For quality control estimates we determined call
rates for each SNP in all samples. Included in
the Dublin and Munich samples were duplicated
DNA samples. Within the UK, Bulgarian and Dublin
sample, we included samples from the HapMap
CEU population to determine genotyping congruence
against the HapMap data. In the sample genotyped by
the Dublin group for marker rs17584522, there
were both duplicate samples and HapMap samples
with which to check genotyping quality control.
fatSNP statistical analyses were as in the previous
study.4 We used a trend test for within-sample
analysis and to combine the data across samples, a
Cochran–Mantel–Haenszel test conditioning by site
as implemented in PLINK version 1.05.16
Imputation was performed on the fatSNP1 sample
with both PLINK16 using the proxy-drop command
and Beagle version 3.0.17
Genomic resequencing
After completion of fatSNP2, we aimed to identify
SNPs within the wider genomic regions not
targeted by the exon-focussed de novo discovery phase.
This was performed using 60 cases drawn randomly
from the Cardiff Full sample. From these, we generated
six pooled samples each containing DNA from 10
samples. PCR primers were designed to span
381988bp of the genomic sequence in and around
ZNF804A (Figure 1). Long-range PCRs were generated
using the Roche Expand Long Template PCR system
(Basel, Switzerland). The PCR products were gel
purified after electrophoresis, and sent to Illumina
(San Diego, CA, USA) for sequencing using Solexa
technology. The resultant single-end reads were as-
sembled and analysed for putative SNPs using both
DNAStar (http://www.dnastar.com) and MAQ (http://
maq.sourceforge.net). We used the default parameters
for DNAStar analysis. The MAQ output was filtered
using previously published thresholds.18
Illumina genotyping
Putative SNPs identified after genomic resequencing
were annotated according to the Illumina OPA (Oligo
Pool All) design criteria, and the files were submitted
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for assay design (http://illumina.com). Designed
SNPs were genotyped in the CEU trios by the Cardiff
laboratory using the GoldenGate Genotyping assay for
VeraCode and analysed using a BeadXpress instru-
ment using VeraScan 1.1 (Ilumina). BeadStudio V3.2
(Illumina) was used to make genotype calls and
compile the data output.
Quantitation of relative allelic expression
To isolate cis-effects from trans-effects on gene
expression in human brain, we measured the relative
expression of each parental copy of ZNF804A in post-
mortem brain mRNA taken from individuals hetero-
zygous for expressed SNP rs4667001, a marker that is
in strong LD (D’ = 1) with rs1344706 in that brain
series (D’ = 0.95 in our association sample). We have
described the methodology and the samples (derived
from cerebral cortex of 149 unrelated anonymous
individuals (86 males, 63 females; mean age 58 years,
s.d. = 19)) in detail elsewhere.19 As this method uses
the level of mRNA expressed from one parental
chromosome to control for that expressed by the
other, the assay is controlled for (and therefore
requires no adjustment for) common confounders
that affect more standard measurements of mRNA in
native human tissue (for example, drug exposure,
agonal state, post-mortem delay, pH, age, and so on).
Meta-analysis of additional data sets
Schizophrenia. To further test the evidence for
association, we combined the data for rs1344706
from our earlier publication4 with data from four
published GWAS studies, one unpublished Swedish
GWAS data set (termed SW3, from P Sullivan/C
Hultman, unpublished data), data from additional
samples we genotyped in house and data from a
ZNF804A candidate gene study from a group who had
contacted us before genotyping their sample10 and
whose data are therefore unbiased with regard to the
result.
The numbers of cases and controls for each of the
samples that we included in the meta-analysis are
given in Supplementary Table 5. Details of the
samples from the published GWAS studies of the
International Schizophrenia Consortium (ISC),5 the
Molecular Genetics of Schizophrenia (MGS) consor-
tium,7 the SGENE-plus consortium6 and of Lencz
et al.20 are given in the primary GWAS publications.
The SW3 sample had been genotyped using an
Affymetrix 6 chip at the Broad Institute of MIT and
was part of the same on-going patient collections as
samples SW1 and SW2 from the ISC data set.21 Details
of the samples used in the candidate gene study of
ZNF804A based upon the Irish Case/Control Study of
Schizophrenia sample are also available in a primary
manuscript.10 It should be noted that those samples
do not overlap with any of the Irish samples provided
by the Dublin group.
Further to their GWAS study, the SGENE-plus and
GROUP consortia obtained genotypes on additional
samples from Europe and China (2865 schizophrenia
cases and 4493 controls) using a Centaurus assay
(Nanogen, San Diego, CA, USA). Details of these are
given in Steinberg et al.11 but briefly, these comprise
schizophrenia case/control samples from China (460/
466), Denmark/Aarhus (236/500), Denmark/Copenha-
gen (513/1338), Germany/Bonn (275/510), Germany/
Munich (178/ 320), Hungary (264/ 223), Norway (201/
357), Russia (483/ 487) and Sweden (255/292).
In addition, we obtained genotype data on a sample
(488 cases and 540 controls) collected by the
Pittsburgh group, details of which are given in
Talkowski et al.22 The group from Dublin (Corvin
and colleagues) provided genotypes based upon a
Taqman assay for an extra set of 352 Irish cases and
178 Irish controls who had not been included in
fatSNP2. The diagnostic and ascertainment practices
were as for the part of their sample described in
O’Donovan et al.4
Subjects who overlapped between studies were
removed as follows. In our previous paper, we
reported data from the MGS European American
sample. However, as the GWAS sample from that
group was larger than what we had used, we include
in this study the MGS GWAS data rather than our
earlier data. The Bulgarian and Irish samples in-
cluded in fatSNP2 substantially overlap with samples
used by the ISC; hence, the ISC data for those
populations were excluded. A data set from Aberdeen
was included in the GWAS of both the ISC and
SGENE-plus. The SGENE-plus data were excluded. It
should be additionally noted that the samples from
Bonn, Munich, and China that were included in the
SGENE-plus study11 did not overlap with the samples
we used in our previous paper.4 We did not include
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Figure 1 fatSNP1 results for ZNF804A. Armitage trend P-
values (log10) for 176 SNPs genotyped during fatSNP
phase 1. Dashed lines represent the boundaries of ZNF804A
transcript (NM_194250). Solid lines represent the region
targeted by genomic resequencing. rs1344706 was the most
significant SNP in the earlier GWAS study (O’Donovan
et al.4). Chromosome position based on NCBI build36.
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data are subsumed in other data sets included here.
We did not include data from the CATIE study24 as the
controls from that study substantially overlap with
those used by the MGS study.7
The use of unadjusted genotype counts is not
appropriate for some samples (for example, SGENE-
plus because of relatedness among the Icelandic
Groups, and MGS because of extensive structure in
the data set); therefore, we used the inverse variance
method of meta-analysis. For each study, variance
was calculated based on the 2 2 contingency table
counts, or the 95% confidence interval values
provided by SGENE-plus, the MGS and the unpub-
lished Swedish GWAS. Heterogeneity between stu-
dies was assessed using Cochran’s Q statistic.
Bipolar disorder. Given that we had previously
reported stronger evidence for association findings
with the inclusion of bipolar samples, to the above
meta-analysis, we added the UK bipolar data set of the
WTCCC.15 Data for additional bipolar samples from
Iceland (n=404) and Norway (n=205) were also
provided by the SGENE-plus/GROUP consortia. To
avoid the problem of shared controls, as before,4 the
WTCCC bipolar data were combined with the UK
schizophrenia cases before testing against the UK
controls. Similarly, the Icelandic and Norwegian
cases were combined with the respective schizo-
phrenia cases from these countries.
Results
Targeted de novo polymorphism detection
We detected no synonymous or non-synonymous
variants in exons 1–3. In exon 4, we detected 21
variants, 14 non-synonymous and 7 synonymous
(Supplementary Table 1).
eQTL results
In the GeneVar CEU database, we found three SNPs in
high LD (r2 = 1) associated with expression of
ZNF804A mRNA (P=0.006). An additional 16 SNPs,
including the best GWAS SNP in ZNF804A
(rs1344706), were associated with expression at
P<0.05 (Supplementary Table 2). The disease-asso-
ciated allele of rs1344706 was associated with higher
expression.
fatSNP study
fatSNP1. Within the target region, 887 SNPs were
listed in HapMap (Rel 23a/phase II Mar08 SNP
database b126) of which 508 had MAF of X0.01. To
these, we added the genotype data for 21 SNPs from
our exonic de novo polymorphism detection. From
these, we identified 209 non-redundant (r2 = 1 in
CEU) markers. Of the 209 markers, we were able to
obtain genotypes for 176 in fatSNP phase 1. Overall,
the genotyped markers provide coverage of 91% of
target alleles with MAF of X0.01 at r2 = 1 and 96%
coverage at r2X0.9. For alleles with MAF of X0.05,
the respective figures are 93 and 97%. Association
results are summarized in Figure 1 and in
Supplementary Table 3. A total of 12 markers (in
addition to rs1344706) met our criteria for follow-up
(Table 1; note that rs12613195 was inc1uded as it
attained the threshold in the full GWAS sample. Also
note that rs6726421 was taken forward as a perfect
proxy for the non-synonymous SNPs described in this
table). Notably, in this subsample of our GWAS
(fatSNP1), three markers yielded slightly stronger
evidence for association than our original GWAS
marker (Table 1). Of these, two (rs1583048 and
rs3931790, r2 = 1) were the putative eQTLs with
strongest evidence for association with expression in
GeneVar (rs7593816, an equally strong eQTL that is
perfectly correlated with those SNPs that failed
genotyping), with the schizophrenia-associated
allele being associated with higher gene expression
(Supplementary Table 2). The other SNP, rs17584522,
is intronic.
fatSNP2. Of the 12 SNPs (Table 1) meeting the
association criteria for follow-up, we selected 8
SNPs based upon r2 < 0.97 (Table 2). In the Cardiff
Full sample, only intronic marker rs17584522 was
associated with schizophrenia at a level of signi-
ficance within one order of magnitude of that of
rs1344706, the initial ‘hit-SNP’ from our earlier paper
(Table 2). Table 2 shows that all SNPs tested in fatSNP
phase 2 are weakly and moderately correlated with
rs1344706 (r2max = 0.43) but are in moderately strong
LD (D’min = 0.7). To test whether any of these
associations are independent of rs1344706, we
performed forward stepwise logistic regression
analysis in the Cardiff Full sample, including all
fatSNP phase 2 SNPs. Only one SNP (rs12613195)
was nominally significant (P=0.021) after allowing
for the effects of rs1344706 (data not shown). Given
the multiple testing of SNPs, we conclude that there
is no convincing evidence for an association signal
independent of rs1344706. Moreover, haplotype
analysis based upon fatSNP phase 2 markers
did not produce results more significant than that
of single marker analysis (data not shown). A
combined analysis of the fatSNP2 samples revealed
rs1344706 as the most significantly associated
SNP (P=8.31106). Single locus data for each of
the individual samples are given in Supplementary
Table 4.
Quality control estimates
In each fatSNP2 sample, SNPs had call rates in cases
and controls of X97% with the exception of
rs12476147 in the UK sample (92% in cases),
rs12613195 in the Munich sample (96% in cases)
and both rs1344706 (93% in cases) and rs17584522 in
the Dublin sample (95 and 93% in cases and controls,
respectively; Supplementary Table 4). In the UK
samples, the more complete imputed genotypes for
rs12476147 gave similar results to the array SNP. No
marker in any of the populations studied had a Hardy-
Weinberg equilibrium P-value < 0.05. Of B1300
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Table 1 Results of fatSNP phase 1
SNP UK fatSNP1 case =479 con=1445
SNP ID Positiona Class Sourceb Casec Conc OR ARM
rs12613195d 185197465 Intronic GWAS 0.27 0.34 0.73 2.19 104
rs17584522 185389974 Intronic fatSNP 0.18 0.25 0.68 2.69 105
rs3931790e 185471620 Intronic eQTL 0.15 0.21 0.66 2.77 105
rs1344706 185486672 Intronic GWAS 0.33 0.41 0.72 4.82 105
rs1583048e 185491385 Intronic eQTL 0.15 0.21 0.65 2.00 105
rs6726421f 185505086 Intronic fatSNP 0.45 0.41 1.22 0.011
rs12476147 185509149 Non-synonymous de novo 0.41 0.37 1.22 0.012
ss177930705 185509348 Non-synonymous de novo 0.04 0.03 1.42 0.077
rs35676856g 185509803 Non-synonymous de novo 0.09 0.06 1.47 0.0052
rs61739290g 185509841 Non-synonymous de novo 0.09 0.07 1.46 0.0050
rs4667001f 185509991 Non-synonymous de novo 0.45 0.41 1.21 0.015
rs1366842f 185510487 Non-synonymous de novo 0.45 0.41 1.22 0.012
rs3731834 185511608 Non-synonymous de novo 0.15 0.17 0.83 0.074
Abbreviations: ARM, Armitage trend test P-value; con, controls; eQTL, expression quantitative trait locus; fatSNP, functional
and tagSNP; GWAS, genome-wide association study; OR, odds ratio; SNP, single-nucleotide polymorphism.
aPosition is based on NCBI build36.
bSource is the phase of study the SNP is derived from.
cCase and Con show minor allele frequency.
dP-value in larger GWAS sample (O’Donovan et al.4) = 2.18 105.
er2 > 0.97 in CEPH sample, GWAS sample and Bulgarian REP1 sample.
fr2 > 0.99 in CEPH sample, GWAS sample and Bulgarian REP1 sample.
gr2 > 0.99 in CEPH sample, GWAS sample and Bulgarian REP1 sample.
Table 2 Results of fatSNP phase 2 and schizophrenia meta-analysis

















SNP ID Class Allele r2 (D’) OR ARM OR CMHa OR CMH OR P
rs12613195 GWAS C 0.33 (0.75) 1.35 1.20 105 1.09 0.038 1.17 6.03 105
rs17584522 fatSNP C 0.24 (0.7) 1.48 6.21 107 1.08 0.080 1.20 5.34 105
rs1344706 GWAS T NA 1.38 7.08 107 1.09 0.026 1.18 8.31 106 1.10 2.54 1011
rs1583048 eQTL A 0.36 (1) 1.46 7.40 106 1.08 0.10 1.18 2.85 104
rs6726421b Tag non-synonymous C 0.43 (0.95) 1.21 0.0022 1.12 0.0050 1.15 1.06 104
rs12476147c Non-synonymous A 0.43 (0.94) 1.23 0.0055 1.11 0.011 1.14 6.54 104
ss177930705 Non-synonymous C 0.01 (1) 1.13 0.49 0.99 0.92 1.04 0.74
rs61739290 Non-synonymous G 0.07 (1) 1.31 0.017 1.03 0.36 1.12 0.099
rs3731834 Non-synonymous C 0.19 (1) 1.26 0.0080 1.02 0.36 1.09 0.072
Abbreviations: ARM, Armitage trend test P-value; CMH, Cochran-Mantel-Haenszel P-value; eQTL, expression quantitative
trait locus; GWAS, genome-wide association study; NA, not applicable; OR, odds ratio; SNP, single-nucleotide
polymorphism.
Cardiff Full = data from O’Donovan et al.;4 REP1= three replication samples (Bulgarian, Dublin 1 and Munich) combined;
fatSNP2=Cardiff Full plus REP1 samples combined; Sz Meta =meta analysis of all available schizophrenia samples.
Allele = associated allele in Cardiff Full; r2(D0) = LD metrics pairwise with rs1344706; OR=odds ratio.
aOne-tailed tests when ORs are in the same direction as Cardiff Full.
bIntronic SNP assayed as a proxy for non-synonymous SNP rs4667001.
cUK extra Schizophrenia data unavailable.
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genotype pairs (HapMap or duplicates) for the 8
independent markers genotyped in our follow-up
study, we observed only 1 genotyping discrepancy.
For rs17584522, which was genotyped by the Dublin
group, the comparison of 72 duplicate samples and 83
HapMap samples revealed no discrepancies.
Meta-analysis
Meta-analysis of rs1344706 in all available schizo-
phrenia data sets provided strong evidence for
association with schizophrenia (P=2.541011) with
an estimated odds ratio (OR) of 1.10 (95% confidence
interval 1.07–14) and no evidence for heterogeneity
across studies (Cochran’s Q statistic, P=0.35, 22 d.f.).
A forest plot of the individual studies is given in
Figure 2 with further details in Supplementary Table
5. A sensitivity analysis (Supplementary Table 6)
revealed that attaining genome-wide significant evi-
dence for association was not dependent on the
inclusion of any one sample, although not unexpect-
edly, the least significant evidence (P=1.19108)
for association was observed when the discovery
sample was removed, consistent with the expected
inflation in the estimated effect size in that sample,
although it is notable that a genome-wide significant
threshold was surpassed even after removal of this
discovery sample.
As before,4 combined analysis of the schizophrenia
and bipolar samples from all studies reported here
provided even stronger evidence (P=4.11013) for
association (Table 3).
For a subset of the non-fatSNP2 samples we were
able to obtain data for additional fatSNP2 markers (or
high-quality proxies). These data (plus for compar-
ison the data for rs1344706 in the same subset) are
presented in Supplementary Table 7. The significance
of association at rs1344706 in the meta-analysis of
these particular samples was more than two orders of
magnitude better than those of the next best marker
(rs17584522).
Complete genomic sequencing
We designed 55 PCR amplimeres with 1 kb overlaps
(average amplimere length 7908 bases, range 6967–
8362). The region spanned B382.3 kb (chr2:
185163292–185545280, NCBI b36) (Figure 1). We
were not successful in amplifying five of the ampli-
meres, representing a total of B8% of the target
sequence (29 341 bases).
We identified 825 putative SNPs. Of these, 245
were either present in the CEU HapMap or had been
genotyped by us in that sample, leaving 580 potential
variants whose LD relationships were unknown. We
were able to design assays for 34% of these SNPs
(n=198). The remaining 66% putative SNPs com-
prised mainly sites in repetitive elements (49%), with
the rest (17%) in unique sequence. We attempted to
confirm 19 of those SNPs that were in repetitive
elements by more routine sequencing methods (Big-
Dye chemistry, Applied Biosystems). Of these, 16
(85%) were not confirmed suggesting that the vast
majority of the sites in highly repetitive elements
were sequencing artefacts.
In the CEU sample, of the 198 SNP assays in our
Illumina panel, 18 did not yield readable genotypes
and an additional 8 assays had a call rate of < 0.95. In
total, we were able to design assays (or obtain data
from HapMap) for a high proportion (B71%) of the
likely genuine SNPs (Supplementary Table 8). Of 172
SNPs for which we obtained new data, only 22 (13%)
with MAF of X0.01 were not previously tagged at
r2 = 1 and only 16 (9%) at r2 = 0.9. This low yield of
untagged SNPs suggests that further sequencing
endeavours (or efforts to genotype the SNPs for which
we could not design Illumina assays) are unlikely to
extract much additional genetic information from the
region. Information about the 172 confirmed SNPs is
provided in Supplementary Table 9.
On the basis of a combination of HapMap and our
in-house polymorphism discovery, the target region
contains a total of 651 confirmed SNPs with MAF of
X0.01. Of these, 87% are tagged at r2 = 1 by the
markers we had already genotyped, whereas 94% are
tagged at r2 = 0.9. Of 13% of markers (n=80) that were
not tagged at r2 = 1, we were able to impute 74%
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Figure 2 Forest plot of rs1344706 schizophrenia meta-
analysis. OR, is odds ratio for each individual study.
Summary is combined OR for all studies. Squares are
drawn proportional to the weight of the sample and lines
represent 95% confidence intervals.
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INFO (information content metric)X0.8 using PLINK
and 60% (n=48) with an r2 score of X0.9 using
Beagle, in the fatSNP1 sample. None was associated
with schizophrenia at a threshold of P<1 104 and
none was highly correlated with rs1344706 (Supple-
mentary Table 10). Including these successfully
imputed SNPs as if they were directly genotyped,
we estimate that our coverage of all known SNPs in
the region with MAF of X0.01 is increased to 97%
(r2 = 1) and to 99% for r2 = 0.9. Importantly, of the
markers (21 out of a total of 651 confirmed markers)
that we could not impute, none was even moderately
highly correlated with rs1344706 (max r2 = 0.13),
making it very unlikely that they could account for
the strong association signal observed at that locus.
To estimate the effectiveness of common variant
discovery in the pooled sequencing analysis, we
determined the number of known HapMaP SNPs
with a frequency of > 0.10, and of > 0.20 that were
detected by pooled genomic sequencing in our
sample. At these thresholds, we detected, respec-
tively, 85 and 87% of known CEU HapMaP SNPs.
These data suggest that the efficiency of mutation
discovery was good for alleles with MAF of > 0.10.
Moreover, as discussed above, given the coverage we
already had for the novel SNPs we detected, it is
unlikely that detection of additional SNPs would
have provided much additional genetic information
with respect to common alleles.
Allelic expression
To identify cis-acting eQTL effects on expression of
ZNF804A, we assayed mRNA samples from 34
individuals heterozygous for non-synonymous SNP
rs4667001 (Figure 3). The G allele at this locus was
associated with a 1.13-fold increase (s.d. 0.08) in
ZNF804A expression (t-test P=2.59107, unequal
variance). rs4667001 has D’ = 1 with rs1344706 in this
sample. The higher expression G allele is always in
phase with risk allele rs1344706T, with this haplo-
type representing B75% of all rs1344706T risk
alleles. The underexpressed A allele at rs4667001
resides on a mixture of haplotypes of which the
majority ( > 70%) carry the non-risk allele
rs1344706G. Thus, consistent with our analysis of
the GeneVar data, the risk allele at rs1344706 is
generally carried by a higher ZNF804A expression
haplotype. If rs1344706 is per se the eQTL respon-
sible for association between that SNP and ZNF804A
expression, we expect only those subjects who are
heterozygous for it to show unequal allelic expression
(as homozygotes for rs1344706 would carry two
functionally equivalent eQTL alleles). Our observed
data were not compatible with this, with there being
no difference in the degree of differential expression
in rs1344706 homozygotes compared with heterozy-
gotes (t-test P=0.84, Figure 3). This suggests that
although rs1344706 is associated with expression, it
is not responsible for it, or at least that it is not the
only cis-acting eQTL. Similarly, analyses of the most
strongly associated eQTLs from GeneVar revealed that
they are also associated with expression, but the
comparison of homozygotes and heterozygotes for
each putative eQTL suggest none are likely the causal
eQTLs (Supplementary Figure 1).
Discussion
Following our original GWAS,4 the association be-
tween schizophrenia and rs1344706, which lies in
intron 2 of ZNF804A, has been independently
replicated in three studies.5,10,11 As our study was
based upon <5% of all common SNPs in the genome,
we assumed that rs1344706 was unlikely to be the
susceptibility variant. Thus, we undertook a fine-
mapping study, the aim of which was to identify the
variant that was directly responsible for association.
In spite of extensive investigation, we were unable to
detect a more strongly associated variant. However,
meta-analysis based upon B60 000 subjects provided
very strong evidence for association between
rs1344706 and schizophrenia (P=2.541011) and
also a combined schizophrenia bipolar phenotype
(P=4.11013).
De novo polymorphism discovery based upon
mutation scanning of all ZNF804A coding exons did
Table 3 Results of genotyping bipolar disorder samples for rs1344706
UK bipolara UK psychosisb PSY metac
Cases n=1735 controls n=2873 Cases = 2377 controls n=2873 Cases n=21 274 controls n=38675
SNP OR ARM OR CMH OR Pd
rs1344706 1.17 5.26 104 1.22 9.74 107 1.11 4.101013
Abbreviations: ARM, Armitage trend test P-value; CMH, Cochran–Mantel–Haenszel P-value; OR, odds ratio; SNP, single-
nucleotide polymorphism.
aUK biploar is UK WTCCC bipolar sample (controls are those used for Cardiff Full).
bUK psychosis is Cardiff Full and UK bipolar samples combined.
cPSY meta is Sz meta samples plus additional data from all available bipolar disorder samples (see text for details).
dP is inverse variance meta-analysis P-value.
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not reveal evidence for the existence of a common
non-synonymous variant (MAF of X0.01) that ex-
plains the original signal in our sample (Table 1), in
the fatSNP2 meta-analysis (Table 2) or in the larger
meta-analyses of those samples for which data were
available for these SNPs (Supplementary Table 7).
The second approach that we applied was to test
SNPs that, in the GeneVar database, were associated
with ZNF804A expression. In fatSNP phase 1, two of
these markers were more significantly associated with
schizophrenia than rs1344706 (Table 1). As those two
markers were in perfect LD, we followed up only one,
rs1583048. As was the case for the non-synonymous
variants, the evidence for association in fatSNP2
(Table 2) and in the larger meta-analyses of those
samples for which data were available for these SNPs
(Supplementary Table 7) was much weaker than for
rs1344706. Therefore, it is likely that the signal
observed at rs1583048 derives from LD (D’ = 1) with
rs1344706. That the signals are not independent was
also supported by the fact that rs1583048 was not
required in the regression model.
Detailed tagging analysis of the ZNF804A locus
based upon HapMap SNPs did not identify any
variants that were more strongly associated in the
Cardiff Full sample or in fatSNP2. Addressing the
possibility that there exists a common variant that
might be more strongly associated than rs1344706,
but that is not present in the HapMap, we undertook
sequencing across most of the genomic region.
Although this uncovered a number of additional
variants not present in the HapMap, these additional
SNPs were well covered by the existing genotyped
SNPs. Despite the fact that the vast majority (99%) of
all the known variation across ZNF804A could be
imputed and/or tagged at least at r2 > 0.9, no addi-
tional markers were more strongly associated than
rs1344706. Moreover, few markers were even moder-
ately correlated with rs1344706. In Supplementary
Table 11, we list all markers with r2 > 0.2 in relation to
rs1344706 and their imputed P-values. If rs1344706
was only weakly or moderately correlated with a true
susceptibility variant, we would expect the associa-
tion signal at that second SNP to be considerably
stronger than that observed at rs1344706. The absence
of such a signal suggests that none of these moder-
ately correlated SNPs are likely to be responsible for
the signal detected at rs1344706. On this basis, we
conclude that rs1344706 is the most likely suscept-
ibility variant.
Several caveats should be mentioned. These are: (1)
we identified a number of putative SNPs that we were
unable to genotype, (2) B8% of the target sequence
was refractory to sequencing and (3) our genomic
sequencing was not 100% sensitive as we identified a
high proportion of, but not all, known variation in the
region. Thus, we cannot conclude with certainty that
the true functional variant did not elude us, but given
that it was not captured in the 651 SNPs (de novo plus
HapMap) for which we had good coverage, and that
very little additional genetic information was ex-
tracted by the novel SNPs that we had detected
through sequencing the genomic region, this does not
seem likely.
At the outset, we assumed it unlikely that a GWAS
study would identify the true pathogenic variant.
However, a recent study5 supports the existence of
very large numbers of common alleles of weak effect.
P = 2.59X10-7 P = 0.84




















gDNA cDNA Homo Hetero
Figure 3 Relative allelic expression data for rs4667001. P is results of t-test of mean relative expression. gDNA is relative
allelic expression ratio for genomic DNA samples heterozygous for rs4667001. cDNA is relative allelic expression ratio for
the corresponding complimentary DNA samples heterozygous for rs4667001. Homo is relative allelic expression ratio for
heterozygous rs4667001 cDNA samples stratified for homozygosity at rs1344706. Hetero is relative allelic expression ratio for
heterozygous rs4667001 cDNA samples stratified for heterozygosity at rs1344706.
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Power considerations suggest few of these can be
expected to achieve high levels of significance even in
samples substantially larger than those we used in our
discovery GWAS. However, although the power to
identify any one specific risk allele is low, the power
to identify one of many alleles is enhanced if there are
very many of these to be detected. One factor dictating
this will be the degree to which true risk variants are
tagged by array SNPs, with weak effects requiring
very high LD for both detection and reliable direc-
tional replication.25 It follows that those risk alleles
that by chance are included on arrays are most likely
to be detected and replicated. Thus, in the context of a
highly polygenic disorder with weak genetic effects
and a underpowered discovery sample, these true
associations that are first detected by GWAS studies
are, as we have observed here, likely to either
correspond to susceptibility alleles, or be in perfect
LD with them.
In terms of functional mechanisms, we observed
that the risk allele of rs1344706 is associated with
higher ZNF804A expression in our analysis of the
GeneVar data. That finding is compatible with the
analysis of Riley et al.10 who reported that the risk
allele at rs1344706 is associated with higher
ZNF804A expression in human brain. However,
although our analysis of allele-specific expression
confirms that rs1344706 is generally carried on a
higher expression haplotype, it does not seem to be
the eQTL responsible for higher expression, suggest-
ing that the relationship between that SNP and
expression is not relevant to disease. Alternatively,
there may be additional eQTLs (and susceptibility
alleles) at the locus that we have failed to uncover.
In the absence of evidence for a non-synonymous
SNP that explains the association or for direct effects
of rs1344706 on expression, if rs1344706 is the true
causal variant, its influence on gene function remains
to be elucidated. It remains possible that it exerts
effects through expression, but similar to many
eQTLs, these are cell specific,26 tissue-region specific
or specific to certain developmental phases. Further
expression studies in samples not available to the
researchers will be required to test these hypotheses.
However, the observations of deletion and partial
duplication CNVs at the ZNF804A in a schizophrenia
and bipolar proband, respectively,11 similarly sug-
gests that simple upregulation of ZNF804A may not
be the mechanism relevant to risk to schizophrenia
and other major psychiatric disorders.
The establishment of ZNF804A as a risk factor for
schizophrenia and bipolar disorder is one of several
successes arising from recent large-scale genetic
studies of major psychiatric disorders. These have
implicated common alleles for psychiatric disorders
at much higher levels of confidence than previous
genetic approaches, among which the most robust
current findings in schizophrenia are ZNF804A,
Neurogranin (NRGN), Trancription Factor 4 (TCF4)
and a locus spanning several megabases of chromo-
some 6 in the region of the major histocompatibility
complex.4–7 In bipolar disorder, calcium channel,
voltage-dependent, L type, alpha 1C subunit (CAC-
NA1C) and ankyrin 3, node of Ranvier (ANK3) have
been strongly supported as susceptibility genes.27 At
least two of the specific loci, ZNF804A and CAC-
NA1C, influence risk for both disorders28 a finding
that supports the hypothesis that schizophrenia and
BD are not aetiologically distinct. Similar to
ZNF804A, in general, the common risk alleles
identified by GWAS have small effect sizes (OR
<1.25), although the associated allele at ANK3 may
have a somewhat larger, but still weak effect (OR
B1.45).27 It is, however, clear that many more
common risk alleles remain to be identified, a
substantial component (at least 30%) of the variance
in risk of schizophrenia being attributable to risk
alleles of very small effect, and many of these also
influence risk of bipolar disorder.5 In the case of
schizophrenia, several rare susceptibility CNVs have
also been detected; in contrast to common alleles,
these have fairly large effect sizes (OR >3) on disease
risk. However, similar to the common alleles, these
CNVs are not specific to individual disorders as
defined by widely used classification systems; the
same CNVs associated with schizophrenia addition-
ally influence risk of other neurodevelopmental
disorders such as autism, epilepsy and mental
retardation.12 Although very little of the genetic risk
of either schizophrenia or bipolar disorder is cur-
rently explained, there are grounds for optimism that
larger studies will reveal more about the origins of
these disorders. Moreover, the existing findings
already challenge current concepts of disease classi-
fication9 and point to some pathophysiological me-
chanisms, for example, the involvement of calcium
channels in bipolar disorder (CACNA1C).
As for the pathophysiological implications of the
present finding, ZNF804A is presently a protein of
unknown function. The amino acid sequence con-
tains a C2H2-type domain characteristic of the
classical zinc-finger (ZnF) family of proteins. These
were originally identified as DNA binding molecules
with a role in transcription, but proteins with this
classic zinc-finger domain are now known to interact
with many other types of molecules, including RNA
and protein, and in doing so, have many roles in
cellular function.29 Until ZNF804A is functionally
characterized, it is not possible to propose specific
cellular processes that link the current genetic finding
to disease risk.
At the whole-organism level, two recent studies
have associated rs1344706 with variation in function.
Esslinger et al.30 reported that the schizophrenia risk
allele at this locus was associated with reduced
connectivity both within DLPFC (dorsolateral pre-
frontal cortex) and between the right and left DLPFC
as indexed by the extent to which activation of these
brain structures was temporally correlated during the
N-back task (a probe for executive function). In
contrast, connectivity was increased between the
DLPFC and the hippocampal formation as well as
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between a number of other structures. More recently,
Walters and colleagues found that the schizophrenia
risk allele at rs1344706 was associated with better
episodic and working memory in individuals with
schizophrenia, but not controls, a finding that they
replicated in a German sample. Given that schizo-
phrenia is associated with reduced cognitive func-
tion, association with better function seems
counterintuitive. However, given the absence of
association with better function in controls, rather
than being associated with cognitive ability, ZNF804A
may be associated with a subtype of schizophrenia in
which cognition is relatively spared. This hypothesis
is in keeping with association between this locus not
just with schizophrenia but also with bipolar dis-
order.31 To what extent, if at all, the results from the
study of Walters and colleagues reflect the observa-
tions of altered connectivity in the earlier study30 is
unclear.
Given that the function of the product of this gene
is currently unknown, determining this is now a
priority in understanding how this genetic associa-
tion translates into pathophysiology. The identifica-
tion of its binding partners, be they DNA, RNA or
protein, will offer the opportunity to identify a set of
further candidate genes, each of which will benefit
from downstream genetic analysis based upon a much
higher prior probability than typical candidate genes
for schizophrenia.
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